Pentostatin (2′-deoxycof ormycin, dCF) in patients with low-grade (B-T-cell) and intermediate- and high-grade (T-cell) malignant lymphomas: Phase II study of the EORTC early clinical trials group

S. Monfardini, R. Sorio, F. Cavalli, T. H. Cerny, M. Van Glabbeke, S. Kaye, J. F. Smyth

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Thirty-seven eligible patients with advanced non-Hodgkin's lymphoma of low-grade, T-cell intermediate- and high-grade histology were treated with pentostatin (2′-deoxycoformycin, dCF) 4 mg2 i.v. weekly for 3 weeks and then every 14 days to be followed after 3 doses by the same dosage every 4 weeks until maximum response or progression. Only patients with no more than two chemotherapy regimens were entered in this trial. All patients had measurable disease, performance status of 1,0 and 2 and adequate bone marrow, renal and liver function. Five of 37 eligible patients experienced a partial response of 8 months' median duration (range 7-12). The response rate was 17% in low-grade, 8% in T-cell intermediate- and high-grade and 14% in cutaneous T cell lymphoma. The only eligible patient with Hodgkin's disease underwent progression while on treatment. One case presented with grade 3 leukopenia and another one died of septicaemia, possibly treatment-related. Elevated but reversible creatinine levels were observed in 13% of patients and conjunctivitis in 7%. The toxicity of dCF at this low-dose schedule was acceptable, but the therapeutic activity in pretreated patients with low-grade, T-cell intermediate- and high-grade and cutaneous T-cell lymphomas was limited.

Original languageEnglish
Pages (from-to)163-168
Number of pages6
JournalOncology
Volume53
Issue number2
Publication statusPublished - Mar 1996

Fingerprint

Pentostatin
T-Cell Lymphoma
Lymphoma
Clinical Trials
T-Lymphocytes
Cutaneous T-Cell Lymphoma
Conjunctivitis
Leukopenia
Hodgkin Disease
Non-Hodgkin's Lymphoma
Disease Progression
Creatinine
Sepsis
Histology
Appointments and Schedules
Therapeutics
Bone Marrow
Kidney
Drug Therapy
Liver

Keywords

  • Malignant lymphomas
  • Pentostatin

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Pentostatin (2′-deoxycof ormycin, dCF) in patients with low-grade (B-T-cell) and intermediate- and high-grade (T-cell) malignant lymphomas : Phase II study of the EORTC early clinical trials group. / Monfardini, S.; Sorio, R.; Cavalli, F.; Cerny, T. H.; Van Glabbeke, M.; Kaye, S.; Smyth, J. F.

In: Oncology, Vol. 53, No. 2, 03.1996, p. 163-168.

Research output: Contribution to journalArticle

@article{31d20411f2274689bc3a8ec22020bf69,
title = "Pentostatin (2′-deoxycof ormycin, dCF) in patients with low-grade (B-T-cell) and intermediate- and high-grade (T-cell) malignant lymphomas: Phase II study of the EORTC early clinical trials group",
abstract = "Thirty-seven eligible patients with advanced non-Hodgkin's lymphoma of low-grade, T-cell intermediate- and high-grade histology were treated with pentostatin (2′-deoxycoformycin, dCF) 4 mg2 i.v. weekly for 3 weeks and then every 14 days to be followed after 3 doses by the same dosage every 4 weeks until maximum response or progression. Only patients with no more than two chemotherapy regimens were entered in this trial. All patients had measurable disease, performance status of 1,0 and 2 and adequate bone marrow, renal and liver function. Five of 37 eligible patients experienced a partial response of 8 months' median duration (range 7-12). The response rate was 17{\%} in low-grade, 8{\%} in T-cell intermediate- and high-grade and 14{\%} in cutaneous T cell lymphoma. The only eligible patient with Hodgkin's disease underwent progression while on treatment. One case presented with grade 3 leukopenia and another one died of septicaemia, possibly treatment-related. Elevated but reversible creatinine levels were observed in 13{\%} of patients and conjunctivitis in 7{\%}. The toxicity of dCF at this low-dose schedule was acceptable, but the therapeutic activity in pretreated patients with low-grade, T-cell intermediate- and high-grade and cutaneous T-cell lymphomas was limited.",
keywords = "Malignant lymphomas, Pentostatin",
author = "S. Monfardini and R. Sorio and F. Cavalli and Cerny, {T. H.} and {Van Glabbeke}, M. and S. Kaye and Smyth, {J. F.}",
year = "1996",
month = "3",
language = "English",
volume = "53",
pages = "163--168",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "2",

}

TY - JOUR

T1 - Pentostatin (2′-deoxycof ormycin, dCF) in patients with low-grade (B-T-cell) and intermediate- and high-grade (T-cell) malignant lymphomas

T2 - Phase II study of the EORTC early clinical trials group

AU - Monfardini, S.

AU - Sorio, R.

AU - Cavalli, F.

AU - Cerny, T. H.

AU - Van Glabbeke, M.

AU - Kaye, S.

AU - Smyth, J. F.

PY - 1996/3

Y1 - 1996/3

N2 - Thirty-seven eligible patients with advanced non-Hodgkin's lymphoma of low-grade, T-cell intermediate- and high-grade histology were treated with pentostatin (2′-deoxycoformycin, dCF) 4 mg2 i.v. weekly for 3 weeks and then every 14 days to be followed after 3 doses by the same dosage every 4 weeks until maximum response or progression. Only patients with no more than two chemotherapy regimens were entered in this trial. All patients had measurable disease, performance status of 1,0 and 2 and adequate bone marrow, renal and liver function. Five of 37 eligible patients experienced a partial response of 8 months' median duration (range 7-12). The response rate was 17% in low-grade, 8% in T-cell intermediate- and high-grade and 14% in cutaneous T cell lymphoma. The only eligible patient with Hodgkin's disease underwent progression while on treatment. One case presented with grade 3 leukopenia and another one died of septicaemia, possibly treatment-related. Elevated but reversible creatinine levels were observed in 13% of patients and conjunctivitis in 7%. The toxicity of dCF at this low-dose schedule was acceptable, but the therapeutic activity in pretreated patients with low-grade, T-cell intermediate- and high-grade and cutaneous T-cell lymphomas was limited.

AB - Thirty-seven eligible patients with advanced non-Hodgkin's lymphoma of low-grade, T-cell intermediate- and high-grade histology were treated with pentostatin (2′-deoxycoformycin, dCF) 4 mg2 i.v. weekly for 3 weeks and then every 14 days to be followed after 3 doses by the same dosage every 4 weeks until maximum response or progression. Only patients with no more than two chemotherapy regimens were entered in this trial. All patients had measurable disease, performance status of 1,0 and 2 and adequate bone marrow, renal and liver function. Five of 37 eligible patients experienced a partial response of 8 months' median duration (range 7-12). The response rate was 17% in low-grade, 8% in T-cell intermediate- and high-grade and 14% in cutaneous T cell lymphoma. The only eligible patient with Hodgkin's disease underwent progression while on treatment. One case presented with grade 3 leukopenia and another one died of septicaemia, possibly treatment-related. Elevated but reversible creatinine levels were observed in 13% of patients and conjunctivitis in 7%. The toxicity of dCF at this low-dose schedule was acceptable, but the therapeutic activity in pretreated patients with low-grade, T-cell intermediate- and high-grade and cutaneous T-cell lymphomas was limited.

KW - Malignant lymphomas

KW - Pentostatin

UR - http://www.scopus.com/inward/record.url?scp=0029869521&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029869521&partnerID=8YFLogxK

M3 - Article

C2 - 8604244

AN - SCOPUS:0029869521

VL - 53

SP - 163

EP - 168

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 2

ER -